DALLAS, Nov. 13, 2020 — Anthony S. Fauci, M.D., the top infectious disease expert in the U.S., will present at the American Heart Association’s Scientific Sessions 2020. His recorded remarks, titled, «COVID-19: Public Health and Scientific Challenges,» is a keynote presentation featured on Tuesday, November 17 at 10:30 a.m. Central Time/11:30 a.m. Eastern Time.

The Association’s annual Scientific Sessions meeting is being held virtually, Friday, November 13 — Tuesday, November 17, 2020. It is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care.

Fauci is a well-known immunologist and has served as the director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, since 1984. He oversees research to diagnose, prevent and treat infectious diseases and is the lead authority in the U.S. on the current COVID-19 pandemic.

While initially thought to be an infection causing disease of the lungs, inflammation of the vascular system and injury to the heart appear to be common features of this novel coronavirus, occurring in 20% to 30% of hospitalized patients and contributing to 40% of deaths[1]. The risk of death from COVID-19-related heart damage appears to be as or more important than other well-described risk factors for COVID-related mortality, such as age, diabetes mellitus, chronic pulmonary disease or prior history of cardiovascular disease[2][3].

Fauci’s presentation and all content from Scientific Sessions is available to all Meeting attendees. Members of the media must register in advance to attend this or any other Scientific Sessions 2020 presentation.

###

For more news at AHA Scientific Sessions 2020, follow us on Twitter @HeartNews #AHA20.

Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

Contact Information:

niaidnews@niaid.nih.gov or 301-402-1663

The AHA is not able to schedule interviews with Dr. Fauci. Please contact his news media office directly.

For AHA Media Inquiries and AHA Expert Perspective:

AHA News Media in Dallas: 214-706-1173;
ahacommunications@heart.org

For Public Inquiries:

1- 800-AHA-USA1 (242-8721)

heart.org and stroke.org

[1] Shi S, Qin M, Shen B, For, 2020]. JAMA Cardiol. 2020. doi: 10.1001/jamacardio.2020.1017.

[2] Callaway E, Cyranoski D, Mallapaty S, Stoye E, Tollefson J. The coronavirus pandemic in five powerful charts. Nature. 2020;579:482-483. doi: 10.1038/d41586-020-00758-2

[3] Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653-1659. doi: 10.1056/NEJMsr2005760
and
Monteil V, Kwon H, Prado P, Hagelkru??ys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado del Pozo C, Prosper F, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 [published online April 2020]. Cell. 2020. doi: 10.1016/j.cell.2020.04.004.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.